More generalized myasthenia gravis (gMG) patients who received Ultomiris (ravulizumab) in the Phase 3 CHAMPION MG trial achieved a favorable clinical response to treatment relative to those taking a placebo, according to…

People with generalized myasthenia gravis (gMG) treated with the experimental therapy rozanolixizumab in a clinical trial generally experienced reductions in disease severity scores regardless of disease duration, prior treatments, and initial disease…

Treatment with Vyvgart (efgartigimod alfa-fcab) over two years was found to safely and effectively ease symptoms of generalized myasthenia gravis (gMG) among participants in an open-label extension study, according to an…

Treatment with the experimental therapy zilucoplan eased symptoms of generalized myasthenia gravis (gMG) across different subgroups of patients participating in the Phase 3 RAISE clinical trial. Trial data showed treatment effects were…